Research guide / GHK-Cu

What is GHK-Cu? A Complete Research Guide.

Updated August 2026 · 10 minute read

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma. This guide separates what peer-reviewed studies show from what reviews propose and what regulators have actually said.

Research information only. This article summarises published research. It is not medical advice, a dosing guide, or a recommendation to use any product. Laboratory and cosmetic-study findings do not predict an individual outcome, and GHK-Cu is not an approved medicine.

01 / Overview

What is GHK-Cu?

GHK-Cu is the copper complex of GHK (glycyl-L-histidyl-L-lysine), a tripeptide that occurs naturally in human plasma, saliva, and urine. It has a strong affinity for copper(II) ions, and the copper complex is the form most often studied.[1]

Reported plasma levels of GHK are around 200 ng/mL at age 20 and decline with age — one reason researchers became interested in it as a marker and modulator of tissue repair. This observation comes from review literature and should be read as context, not as a basis for supplementation.[2]

Unlike the incretin peptides covered elsewhere in this hub, GHK-Cu has no large randomised clinical trial programme. Its evidence base is mostly laboratory and animal research, gene-expression analyses, and small human studies of topical cosmetic formulations. That difference shapes everything below.

View the GHK-Cu research listing

02 / Mechanism

How does GHK-Cu work?

GHK's proposed actions centre on its copper binding. Reviews describe it as a carrier that delivers copper to cells and as a modulator of many biochemical pathways involved in tissue maintenance and repair.[1], [2]

Aspect	What research reports	Research relevance
Copper binding	GHK binds copper(II) with high affinity and occurs as a copper complex in human plasma.	Proposed as a delivery and modulation mechanism for copper-dependent repair processes.
Matrix synthesis	Cell studies report increased synthesis of collagen, elastin, and glycosaminoglycans.	Central to its investigation in skin biology and wound-healing research.
Gene expression	Reviews report modulation of thousands of human genes in cell models.	Hypothesis-generating only; genomic changes in vitro do not equal clinical effects.

Gene-expression analyses cited in the review literature report that GHK can up- or down-regulate a large number of human genes in cell models. These are observational genomic findings from laboratory systems; they do not establish therapeutic effects in people and should not be read as proof of any clinical benefit.

03 / Published evidence

Peer-reviewed findings

GHK was first characterised in 1973, when Pickart, Thayer, and Thaler reported that a synthetic tripeptide analogous to a human serum factor increased survival of normal liver cells and stimulated growth of cultured hepatoma cells at nanomolar concentrations. This is the original characterisation study, not a clinical trial.[3]

A 2015 peer-reviewed review in BioMed Research International summarised decades of work: GHK stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and decorin in cell systems; modulates metalloproteinases and their inhibitors; and accelerated wound healing in animal models including rats, mice, and pigs. These are predominantly preclinical findings.[2]

In a small 1998 pilot study of 20 healthy volunteers, a topical copper-binding peptide cream applied for one month increased dermal procollagen synthesis in 5 of 10 users on immunohistologic assessment — comparable to tretinoin (4 of 10) and vitamin C (5 of 10) in the same study. The study was small, short, and not a registration-quality trial.[4]

A 2018 review in the International Journal of Molecular Sciences surveyed gene-expression data and proposed broad cell-protective and tissue-repair actions. Both cited reviews were co-authored by Loren Pickart, the researcher who discovered GHK and who has commercial interests in copper-peptide products — relevant context when weighing the strength of the proposals.[1]

04 / Evidence landscape

How the evidence is structured

GHK-Cu does not have a registered Phase 1–3 clinical programme of the kind seen for approved drug candidates. The table below maps the main categories of published evidence instead.

Category	Example	Scale	What it can show
Original characterisation	Pickart, Thayer & Thaler, 1973	Laboratory cell studies	Biological activity exists; nothing about human outcomes
Reviews of preclinical work	BioMed Res Int 2015 · Int J Mol Sci 2018	Decades of cell and animal studies	Mechanistic hypotheses and consistency across models
Small human topical studies	Abdulghani et al., 1998	20 volunteers, 1 month	Early signals for skin measures; not registration-quality

This mapping reflects the published records reviewed for this August 2026 update. Absence of a large trial programme is itself a finding: claims beyond the evidence should be treated with caution.[1], [2], [3]

Afiya Labs lists a GHK-Cu reference material for laboratory research. The catalogue entry is not a medicine listing and is not presented as suitable for human use.

See the GHK-Cu catalogue entry

Shop GHK-Cu pen

05 / Safety evidence

What safety evidence exists?

Topical GHK-Cu has been used in cosmetic products for decades, and the review literature reports it as generally well tolerated on skin. However, cosmetic tolerability data are not equivalent to pharmaceutical safety trials, and most published safety experience relates to topical, not injectable, use.[2]

The U.S. FDA has identified potential significant safety risks for GHK-Cu for injectable routes of administration and placed it in Category 2 of its interim compounding policy, while GHK-Cu for non-injectable routes sits in Category 1 (under evaluation). Category placement is a regulatory risk signal, not a full safety assessment.[5], [6]

There are no large, long-term human safety trials of injectable GHK-Cu. Anyone reading claims about injectable use should weigh them against that absence of controlled human data.

06 / Regulators

Status in the US, Europe, and UAE

United States

GHK-Cu is not an FDA-approved drug. Under the FDA's interim compounding policy, GHK-Cu for injectable routes of administration is in Category 2 (potential significant safety risks), while GHK-Cu for non-injectable routes is in Category 1 (under evaluation); the FDA has said it intends to consult its Pharmacy Compounding Advisory Committee on the non-injectable nomination. These categories concern pharmacy compounding and are not a marketing authorisation.[5], [6]

European Union

GHK-Cu is not authorised as a medicine in the EU. The copper-peptide form (copper tripeptide-1) appears widely as a cosmetic ingredient, which is a separate regulatory category from medicines and does not imply any approved therapeutic effect.[1]

United Arab Emirates

The Emirates Drug Establishment maintains the UAE's public registered medical product directory. We did not rely on a directory search to infer approval, non-approval, legality, availability, or permission for use of any specific product; those questions require confirmation from the EDE. Approved medicines in the UAE are dispensed through licensed channels.[7]

07 / Quick answers

Frequently asked questions

Is GHK-Cu an approved medicine?

No. GHK-Cu is not approved as a drug in the US or authorised as a medicine in the EU. It is widely used as a cosmetic ingredient (copper tripeptide-1), which is a different regulatory category with different evidence requirements.

Is GHK-Cu natural?

GHK is a naturally occurring tripeptide found in human plasma, saliva, and urine, where it exists largely as a copper complex. Research materials are synthetically produced versions of the same molecule.

What does the research actually show?

Strong laboratory and animal evidence for effects on collagen synthesis and wound-healing models, plus small human studies of topical cosmetic use. There are no large randomised controlled trials, and no completed pharmaceutical development programme.

Why does the FDA treat injectable and non-injectable GHK-Cu differently?

Under its interim compounding policy, the FDA placed injectable GHK-Cu in Category 2 because it identified potential significant safety risks, while the non-injectable nomination had sufficient supporting information to remain under evaluation in Category 1. The distinction is about route-specific risk in compounding, not an approval decision.

Do the gene-expression studies prove anti-ageing effects?

No. Gene-expression changes observed in cell models are hypothesis-generating. They show which pathways the molecule touches in a laboratory system; they cannot demonstrate that any outcome occurs in people.

What does the UAE directory show?

It is a public register of medical products. This guide does not turn a directory search result — or the absence of one — into a claim about approval, legality, or permitted use. The EDE is the appropriate authority for a current determination.

08 / Sources